Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib and Bortezomib in Relapsed/Refractory Mantle Cell Lymphoma
NCT02356458Phase 2Terminated
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Aug 2015
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of ibrutinib in mantle cell lymphoma (MCL), sponsored by Swiss Group for Clinical Cancer Research. Started Aug 2015; status: terminated.
02
Drugs
ibrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02356458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02356458.